Clopidogrel is a first generation thienopyridine P2Y12 receptor inhibitor. Clopidogrel acts as a cardioprotective antithrombotic/anticoagulant that is clinically used to treat coronary artery disease and peripheral vascular disease and also to prevent myocardial infarction and stroke.
| Cas No. | 120202-66-6 |
|---|---|
| Purity | ≥98% |
| Formula | C16H16ClNO2S • H2SO4 |
| Formula Wt. | 419.90 |
| Chemical Name | (αS)-α-(2-Chlorophenyl-6,7-dihydrothieno[3,2-c]- pyridine-5(4H)-acetic acid methyl ester |
| IUPAC Name | methyl(2S)-2-(2-chlorophenyl)-2-(6,7-dihydro-4H-thieno[3,2-c]pyridin-5-yl)acetate;sulfuric acid |
| Synonym | Clopidogrel hydrogen sulfate; Plavix |
| Melting Point | 184°C |
| Solubility | Soluble in water (84mg/mL), methanol, ethanol (84mg/mL), and DMSO(84mg/mL) |
| Appearance | White to off white powder |
| Store Temp | Ambient |
|---|---|
| Ship Temp | Ambient |
| MSDS | C4658 MSDS PDF |
|---|---|
| Info Sheet | C4658 Info Sheet PDF |
Thomas MR, Storey RF. Impact of aspirin dosing on the effects of P2Y12 inhibition in patients with acute coronary syndromes. J Cardiovasc Transl Res. 2014 Feb;7(1):19-28. PMID: 24309957.
Ferri N, Corsini A, Bellosta S. Pharmacology of the new P2Y12 receptor inhibitors: insights on pharmacokinetic and pharmacodynamic properties. Drugs. 2013 Oct;73(15):1681-709. PMID: 24114622.
Sato Y, Miyashita A, Iwatsubo T, Usui T. Conclusive identification of the oxybutynin-hydrolyzing enzyme in human liver. Drug Metab Dispos. 2012 May;40(5):902-906. PMID: 22293119.
